GPT and Hepatic fibrosis: The potential influence of HBeAg status, HBV DNA concentration, liver fibrosis, age and gender of patients, the type of previous therapy (LAM vs. LAM → ETV) and the presence of the polymerase sequence mutations on the increased ALT activity has been evaluated.